ANI Pharmaceuticals, Inc.
ANIP
$57.96
$0.460.80%
| Weiss Ratings | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | D+ | |||
| Rating Factors | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.92 | |||
| Price History | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 6.58% | |||
| 30-Day Total Return | 1.92% | |||
| 60-Day Total Return | -2.23% | |||
| 90-Day Total Return | -0.89% | |||
| Year to Date Total Return | 4.55% | |||
| 1-Year Total Return | 4.24% | |||
| 2-Year Total Return | 38.49% | |||
| 3-Year Total Return | 38.23% | |||
| 5-Year Total Return | -5.40% | |||
| 52-Week High % Change | -18.80% | |||
| 52-Week Low % Change | 9.52% | |||
| Price | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $70.81 | |||
| 52-Week Low Price | $52.50 | |||
| 52-Week Low Price (Date) | Dec 19, 2024 | |||
| 52-Week High Price (Date) | Mar 25, 2024 | |||
| Valuation | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.12B | |||
| Enterprise Value | 1.63B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.45 | |||
| Earnings Per Share Growth | -189.91% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 2.01 | |||
| Price/Book (Q) | 2.77 | |||
| Enterprise Value/Revenue (TTM) | 2.93 | |||
| Price | $57.96 | |||
| Enterprise Value/EBITDA (TTM) | 19.81 | |||
| Enterprise Value/EBIT | 74.61 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 19.40M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -22.92% | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 218 634 3500 | |||
| Address | 210 Main Street West Baudette, MN 56623 | |||
| Website | www.anipharmaceuticals.com | |||
| Country | United States | |||
| Year Founded | 2001 | |||
| Profitability | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 3.92% | |||
| Profit Margin | -1.27% | |||
| Management Effectiveness | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 1.25% | |||
| Return on Equity | -- | |||
| Income Statement | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 555.46M | |||
| Total Revenue (TTM) | 555.46M | |||
| Revenue Per Share | $28.63 | |||
| Gross Profit (TTM) | 332.11M | |||
| EBITDA (TTM) | 82.13M | |||
| EBIT (TTM) | 21.80M | |||
| Net Income (TTM) | -7.09M | |||
| Net Income Avl. to Common (TTM) | -8.72M | |||
| Total Revenue Growth (Q YOY) | 12.52% | |||
| Earnings Growth (Q YOY) | -343.12% | |||
| EPS Diluted (TTM) | -0.45 | |||
| EPS Diluted Growth (Q YOY) | -380.73% | |||
| Balance Sheet | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 153.28M | |||
| Cash Per Share (Q) | $7.90 | |||
| Total Current Assets (Q) | 521.30M | |||
| Total Preferred Equity (Q) | 24.85 | |||
| Total Equity (Q) | 430.80M | |||
| Current Ratio (Q) | 2.745 | |||
| Book Value Per Share (Q) | $20.74 | |||
| Total Assets (Q) | 1.29B | |||
| Total Current Liabilities (Q) | 189.93M | |||
| Total Debt (Q) | 632.31M | |||
| Total Liabilities (Q) | 856.58M | |||
| Total Common Equity (Q) | 405.95M | |||
| Cash Flow | ANIP - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -398.82M | |||
| Cash from Financing (TTM) | 257.93M | |||
| Net Change in Cash (TTM) | -48.06M | |||
| Levered Free Cash Flow (TTM) | 50.12M | |||
| Cash from Operations (TTM) | 92.90M | |||
